HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on PDS Biotechnology (NASDAQ:PDSB) and maintains a $21 price target.
June 06, 2023 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotechnology receives a reiterated Buy rating from HC Wainwright & Co. with a maintained $21 price target.
The reiterated Buy rating and maintained $21 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for PDS Biotechnology. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100